Table 3 Retreatment criteria in key randomised controlled trials of anti-VEGF therapies in nAMD.
Study | Regimen in flexible dosing arm | OCT modality | Retreatment criteria |
|---|---|---|---|
CATT [82] | 1 mandatory injection followed by PRN dosing | Time domain | Signs of active neovascularisation defined as fluid on OCT, new or persistent haemorrhage, decreased VA compared with previous examination, or dye leakage or increased lesion size on FA |
HARBOR [83] | 3 mandatory monthly injections followed by PRN dosing | Spectral domain | ≥5-letter decrease in vision from the previous visit or any evidence of disease activity on OCT (e.g., IRF, SRF, or sub-RPE fluid) |
GEFAL [84] | 3 mandatory monthly injections followed by PRN dosing | Spectral domain or time domain | At least one of: loss of ≥5 letters from the previous visit with no obvious atrophy or subretinal fibrosis and with fluid on OCT; and/or active exudation on OCT (SRF unless stable since the last 3 monthly injections, macular oedema with IRF, or increase in central subfield macular thickness of at least 50 µm compared with the previous examination); and/or increased MNV area or persistence of leakage on angiography since the previous visit; and/or new or persistent subretinal or intraretinal macular haemorrhage |
VIEW 1 and 2 [36] | PRN dosing from week 52 to week 96 | Time domain | At least one of: new or persistent fluid on OCT, increase in central subfield thickness ≥100 µm compared with the lowest previous value, loss of ≥5 ETDRS letters from the best previous score in conjunction with recurrent fluid on OCT, new-onset classic neovascularisation, new or persistent leak on FA, new macular haemorrhage, or time lapse of at least 12 weeks since the previous injection |
FLUID [19] | 3 mandatory monthly injections followed by a T&E regimen | Spectral domain | Loss of BCVA of ≥5 letters from the best BCVA recorded since baseline, new retinal haemorrhage, or presence of fluid on OCT. For the intensive arm, fluid was defined as the presence of any IRF, SRF, or both. For the relaxed arm, fluid was defined as the presence of any IRF and any SRF of >200 µm in height at the subfoveal centre |
